Literature DB >> 11072960

Adverse drug reactions: definitions, diagnosis, and management.

I R Edwards1, J K Aronson.   

Abstract

We define an adverse drug reaction as "an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product." Such reactions are currently reported by use of WHO's Adverse Reaction Terminology, which will eventually become a subset of the International Classification of Diseases. Adverse drug reactions are classified into six types (with mnemonics): dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure). Timing, the pattern of illness, the results of investigations, and rechallenge can help attribute causality to a suspected adverse drug reaction. Management includes withdrawal of the drug if possible and specific treatment of its effects. Suspected adverse drug reactions should be reported. Surveillance methods can detect reactions and prove associations.

Mesh:

Year:  2000        PMID: 11072960     DOI: 10.1016/S0140-6736(00)02799-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  691 in total

1.  Adverse events following acupuncture: prospective survey of 32 000 consultations with doctors and physiotherapists.

Authors:  A White; S Hayhoe; A Hart; E Ernst
Journal:  BMJ       Date:  2001-09-01

Review 2.  Methods and systems to detect adverse drug reactions in hospitals.

Authors:  P A Thürmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Determinants of signal selection in a spontaneous reporting system for adverse drug reactions.

Authors:  E P van Puijenbroek; K van Grootheest; W L Diemont; H G Leufkens; A C Egberts
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

4.  Developing a taxonomy for research in adverse drug events: potholes and signposts.

Authors:  J R Nebeker; J F Hurdle; J Hoffman; B Roth; C R Weir; M H Samore
Journal:  Proc AMIA Symp       Date:  2001

5.  A comparative study of QT prolongation with serotonin reuptake inhibitors.

Authors:  Ana Ojero-Senard; Justine Benevent; Emmanuelle Bondon-Guitton; Geneviève Durrieu; Leila Chebane; Melanie Araujo; Francois Montastruc; Jean-Louis Montastruc
Journal:  Psychopharmacology (Berl)       Date:  2017-08-03       Impact factor: 4.530

6.  Nevirapine induced exfoliative dermatitis in an HIV-infected patient.

Authors:  Anoosha P Bhandarkar; Priydarshini B Kop; Varadraj V Pai
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

7.  Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand.

Authors:  Mira Harrison-Woolrych; Simran Maggo; Ming Tan; Ruth Savage; Janelle Ashton
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

Review 8.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

9.  Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach.

Authors:  Petra A Thuermann; Roland Windecker; Joachim Steffen; Markus Schaefer; Ute Tenter; Erich Reese; Hermann Menger; Klaus Schmitt
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  Provider management of and satisfaction with laboratory testing in the nursing home setting: results of a national internet-based survey.

Authors:  Brian H Shirts; Subashan Perera; Joseph T Hanlon; Yazan F Roumani; Stephanie A Studenski; David A Nace; Michael J Becich; Steven M Handler
Journal:  J Am Med Dir Assoc       Date:  2009-01-08       Impact factor: 4.669

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.